The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies
Open accessAbstract
Background Dementia is a major health concern for which prevention and treatment strategies remain elusive. Lowering high blood pressure with specific antihypertensive medications (AHMs) could reduce the burden of disease. We investigated whether specific AHM classes reduced the risk for dementia.Methods We did a meta-analysis of individual participant data from eligible observational studies published between Jan 1, 1980, and Jan 1, 2019. Cohorts were eligible for inclusion if they prospectively recruited community-dwelling adults; included more than 2000 participants; collected data for dementia events over at least 5 years; had measured blood pressure and verified use of AHMs; included in-person exams, supplemented with additional data, to capture dementia events; and had followed up cases for mortality. We assessed the association of incident dementia and clinical Alzheimer's disease with use of five AHM classes, within strata of baseline high (systolic blood pressure [SBP] ≥140 mm Hg or diastolic blood pressure [DBP] ≥90 mm Hg) and normal (SBP <140 mm Hg and DBP <90 mm Hg) blood pressure. We used a propensity score to control for confounding factors related to the probability of receiving AHM. Study-specific effect estimates were pooled using random-effects meta-analyses.Results Six prospective community-based studies (n=31 090 well phenotyped dementia-free adults older than 55 years) with median follow-ups across cohorts of 7-22 years were eligible for analysis. There were 3728 incident cases of dementia and 1741 incident Alzheimer's disease diagnoses. In the high blood pressure stratum (n=15 537), those using any AHM had a reduced risk for developing dementia (hazard ratio [HR] 0·88, 95% CI 0·79-0·98; p=0·019) and Alzheimer's disease (HR 0·84, 0·73-0·97; p=0·021) compared with those not using AHM. We did not find any significant differences between one drug class versus all others on risk of dementia. In the normal blood pressure stratum (n=15 553), there was no association between AHM use and incident dementia or Alzheimer's disease.Interpretation Over a long period of observation, no evidence was found that a specific AHM drug class was more effective than others in lowering risk of dementia. Among people with hypertensive levels of blood pressure, use of any AHM with efficacy to lower blood pressure might reduce the risk for dementia. These findings suggest future clinical guidelines for hypertension management should also consider the beneficial effect of AHM on the risk for dementia.Funding The Alzheimer's Drug Discovery Foundation and the National Institute on Aging Intramural Research Program.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One meta-analysis of IPD cohorts comprising 31,090 dementia free adults at baseline with followup of ≥ 5 years found those with hypertension taking any antihypertensive were at lower risk than those not (HR 0.88 0.79-0.98) but no difference between classes of drugs. (191)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [191]
In the citing paper
“Four meta-analyses of blood pressure medications to lower high blood pressure with six studies overlap have provided combined estimates of effects. All meta-analyses suggest reduced dementia in those in the interventions arms for outcomes of any dementia as well as clinically diagnosed Alzheimer's disease.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [83]
In the citing paper
“The third included used individual participant data from six observational studies; (dementia 0·9, 0·8–1·0 and Alzheimer's disease 0·8, 0·7–1·0; figure 4 ).”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [83]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Multiple imputation of discrete and continuous data by fully conditional specification
van Buuren, S. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280206074463 · Cited by 2,827
Williamson (2019) · doi:10.1001/jama.2018.21442 · Cited by 1,246
Self-citationGenome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Self-citationIadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., Gulati, M., Kamel, H., Knopman, D. S., Launer, L. J., et al. (2016) · Hypertension · doi:10.1161/hyp.0000000000000053 · Cited by 746
Self-citationComparison of Propensity Score Methods and Covariate Adjustment
Elze, M. C., Gregson, J., Baber, U., Williamson, E., Sartori, S., Mehran, R., Nichols, M., Stone, G. W., & Pocock, S. J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.060 · Cited by 713
(2003) · Neuroepidemiology · doi:10.1159/000072920 · Cited by 672
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
RetractedDementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation
Claassen, J. A. H. R., Thijssen, D. H. J., Panerai, R. B., & Faraci, F. M. (2021) · Physiological Reviews · doi:10.1152/physrev.00022.2020 · Cited by 915
The ARIC (Atherosclerosis Risk In Communities) Study
Wright, J. D., Folsom, A. R., Coresh, J., Sharrett, A. R., Couper, D., Wagenknecht, L. E., Mosley, T. H., Ballantyne, C. M., Boerwinkle, E. A., Rosamond, W. D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.035 · Cited by 552
Self-citationHypertension, Neurovascular Dysfunction, and Cognitive Impairment
Santisteban, M. M., Iadecola, C., & Carnevale, D. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.18085 · Cited by 279
Metadata
- Authors
- Ding, J., Davis-Plourde, K. L., Sedaghat, S., Tully, P. J., Wang, W., Phillips, C., Pase, M. P., Himali, J. J., Gwen Windham, B., Griswold, M., Gottesman, R., Mosley, T. H., White, L., Guðnason, V., Debette, S., Beiser, A. S., Seshadri, S., Ikram, M. A., Meirelles, O., Tzourio, C., & Launer, L. J.
- Affiliations
- National Institutes of Health (US)
- Northwestern University (US)
- Inserm (FR)
- University of Mississippi Medical Center (US)
- The University of Melbourne (AU)
- Boston University (US)
- Johns Hopkins University (US)
- Pacific Health Research and Education Institute (US)
- Erasmus MC (NL)
- Corresponding author
- Launer, Lenore J
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 19
- Issue
- 1
- Pages
- 61-70
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC7391421
- OpenAlex
- W2984201353
- Cited by
- 312
- References
- 30
- Citations by year
- 2026: 24 · 2025: 39 · 2024: 67 · 2023: 45 · 2022: 47 · 2021: 59 · 2020: 29
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Swinburne figshare (Swinburne University of Technology) (submittedVersion)
- Funders
- Alzheimer's Drug Discovery Foundation (20150703)
- National Institute on Aging
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- antihypertensive drugs, dementia, Alzheimer's disease, hypertension, blood pressure, incident dementia risk, drug classes, individual patient data, community-dwelling adults, older adults, dementia prevention, antihypertensive drug safety, propensity score matching, confounding by indication, drug-drug interactions, adverse drug reactions, stroke, diabetes mellitus
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Antihypertensive Agents, Dementia, Female, Humans, Male, Middle Aged, Prospective Studies, Risk, Cohort Studies, Incidence, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies. https://app.cochat.ai/papers/10.1016/s1474-4422(19)30393-x
- The paper
- Ding, J., Davis-Plourde, K. L., Sedaghat, S., Tully, P. J., Wang, W., Phillips, C., Pase, M. P., Himali, J. J., Gwen Windham, B., Griswold, M., Gottesman, R., Mosley, T. H., White, L., Guðnason, V., Debette, S., Beiser, A. S., Seshadri, S., Ikram, M. A., Meirelles, O., . . . Launer, L. J. (2020). Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(19)30393-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.